- 1 **Title**: SARS-CoV-2 lethality decreased over time in two Italian Provinces.
- 3 Authors: Maria Elena Flacco¹, Cecilia Acuti Martellucci², Francesca Bravi³, Giustino Parruti⁴, Alfonso
- 4 Mascitelli⁵, Lorenzo Mantovani⁶, Lamberto Manzoli¹*.
- 6 **Affiliations**:

5

13

19

21

- 7 Department of Medical Sciences, University of Ferrara, Italy;
- 8 ² Department of Biomedical Sciences and Public Health, University of the Marche Region, Ancona, Italy;
- 9 ³ "Sant'Anna" University Hospital of Ferrara, Italy;
- 10 ⁴ Local Health Authority of Pescara, Italy;
- 11 ⁵ Regional Healthcare Agency of Abruzzo, Pescara, Italy.
- 12 ⁶ School of Medicine and Surgery, University Bicocca, Milan, Italy.
- 14 **Short title:** SARS-CoV-2 lethality decrease over time.
- 15 **Key words**: SARS-CoV-2; COVID-19; Case-fatality rate; Mortality.
- * lmanzoli@post.harvard.edu (LM)
- 17 **Word count**: 1440.
- 18 Number of Tables/Figures: 3.
- These authors equally contributed to this manuscript.
- Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CVD,
- 23 cardiovascular disease; HR, hazard ratio; RT-PCR, reverse transcription polymerase chain reaction; SARS-
- 24 CoV-2, severe acute respiratory syndrome coronavirus 2; SDO, hospital discharge abstract (scheda di
- 25 dimissione ospedaliera).

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

Abstract Background Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet available. This retrospective cohort study aimed to evaluate whether SARS-CoV-2 case-fatality rate decreased with time, adjusting for main potential confounders. Methods and findings We included all SARS-CoV-2 infected subjects diagnosed in Ferrara and Pescara provinces, Italy. Information were collected from local registries, clinical charts, and electronic health records. We compared the case-fatality rate of the subjects diagnosed during April and March, 2020. We used Cox proportional hazards analysis and random-effect logistic regression, adjusting for age, gender, hypertension, type II diabetes, major cardiovascular diseases (CVD), chronic obstructive pulmonary diseases (COPD), cancer and renal disease. The sample included 1946 subjects (mean age 58.8y; 45.7% males). 177 persons deceased, after a mean of 11.7 days of follow-up. From March to April, the case-fatality rate significantly decreased in the total sample (10.8% versus 6.0%; p<0.001), and in any subgroup of patients. Large reductions of the lethality were observed among the elderly (from 30.0% to 13.4%), and subjects with hypertension (23.0% to 12.1%), diabetes (30.3% to 8.4%), CVD (31.5% to 12.1%), COPD (29.7% to 11.4%), and renal disease (32.3% to 11.5%). In April, the adjusted hazard ratio of death was 0.42 (95% Confidence Interval: 0.29-0.60). The mean age of those who died substantially increased from March (77.9±10.8y) to April $(86.9\pm7.7y)$. **Conclusions** In this sample, SARS-CoV-2 case-fatality rate decreased considerably over time, supporting recent claims of a substantial improvement of SARS-CoV-2 clinical management. The findings are inevitably preliminary and require confirmation.

Author summary

Why was this study done?

- Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet available.
- What did the researchers do and find?
- We carried out a retrospective cohort study on 1946 SARS-CoV-2 infected subjects from two Italian provinces, evaluating the potential variation of the case-fatality rate over time.
 - From March to April, in both univariate and multivariable analyses, SARS-CoV-2 case-fatality rate significantly and substantially decreased, overall and in any subgroup of subjects.

What do these findings mean?

• The therapies and clinical management of SARS-CoV-2 infected subjects might have substantially improved over time.

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

Introduction As of May 18, 2020, SARS-CoV-2 pandemic has caused 320,000 deaths worldwide [1], with largely discrepant case-fatality rates across countries (from <1% to 16%) [2], likely due to differences in population age structure [3, 4], variations in testing policies and case recording [5], and/or preparedness of the healthcare system, which in turn is affected by the intensity of the spread [4, 5]. Since the start of the pandemic, Italy has been among the countries with the highest death toll, with more than 32,000 recorded deaths [1], and an estimated case-fatality rate of 14% [2], which peaked at 20% among the citizens aged ≥ 80 years [6]. In the last few weeks, some clinicians suggested that SARS-CoV-2 lethality decreased considerably, mostly as a consequence of more tailored therapeutic approaches [7-11]. Although the claims were made by expert physicians, actively engaged in the care of infected patients, the available evidence is anecdotal or based upon case-studies. We analysed the data of all infected cases in two Italian Provinces to evaluate whether SARS-CoV-2 casefatality rate decreased with time, adjusting for main potential confounders. Methods This retrospective cohort study included all subjects infected with SARS-CoV-2, diagnosed in the Provinces of Ferrara and Pescara, between March 3 (the onset date of the first cases), and April 25, 2020. All participants were followed up to May 5, 2020. All infections were diagnosed by the central laboratories of Ferrara University Hospital or Pescara Hospital through RT-PCR (Reverse transcription polymerase chain reaction) test on nasopharyngeal swabs, and were confirmed by the Italian National Institute of Health. Information on age, gender, and pre-existing conditions of all participants were collected from local registries, clinical charts (for hospitalized patients), and through data-linkage with hospital discharge abstracts (Italian SDO) and the National database of drug prescription. Electronic databases were queried from the day of the diagnosis until January 1st, 2015. All data have been revised manually by two physicians (LM and MEF), and the following conditions have been included in the analyses: hypertension, type II

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

with CVD and renal diseases significantly increased (Table 1).

diabetes, major cardiovascular diseases (heart failure, myocardial infarction and stroke - CVD), chronic obstructive pulmonary diseases (COPD, bronchitis, pneumonia, asthma, and emphysema), malignant tumors and renal disease. The study complies with the Declaration of Helsinki, the research protocol was approved by the Ethics Committee of the Emilia-Romagna Region (code 287, approved on March 24, 2020), and the requirement for informed consent was waived because of the retrospective and pseudo-anonymized nature of the data. **Data Analysis** We compared the case-fatality rate (fatal / confirmed cases) during the first 29 days after the index day (from March 3 to March 31) with that of the second half of the period (days 30-53; from April 1 to April 25). The differences between the two periods were initially evaluated using t-test for continuous variables, and chisquared test for categorical ones. The potential independent predictors of death were then evaluated using Cox proportional hazards analysis (using the data censored at May 5, to include ≥10 days of follow-up). All covariates were included a priori in the model in their original form, with the exception of age, which was treated as either continuous or ordinal, to explore the association between the outcome and several age classes. Schoenfeld's test was used to assess the validity of proportional hazards assumption, and Nelson-Aalen cumulative hazard estimates to check the validity of constant incidence ratios during the follow-up [12]. Using the data censored at 20 days of follow-up, a random-effect logistic regression was also fit, with province as the cluster unit. The same above criteria were used to build the final model. Missing data were <5% in all primary analyses; therefore, no missing imputation technique was adopted. Statistical significance was defined as a two-sided p-value<0.05, and all analyses were carried out using Stata, version 13.1 (Stata Corp., College Station, TX, 2014). **Results** The sample consisted of 1946 subjects (mean age 58.8y; 45.7% males); of them, 31.2% were hypertensive, 12.3% diabetics, and 16.6% with CVD. Some of the characteristics of the sample significantly varied from March to April. Infected subjects were older by 5.6 years, and the proportion of females, diabetics, subjects

Table 1. Characteristics of the sample, overall and by time of SARS-CoV-2 infection diagnosis after the first case (March 3, 2020).

	Total sample	March 2020 ^a	April 2020 ^b	p*
	(n=1946)	(n=1244)	(n=702)	
Mean age (SD), years	58.8 (21.3)	56.8 (20.0)	62.4 (23.0)	< 0.001
Age-class in years, %				
- <18	3.5	3.9	2.8	0.2
- 18-39.9	14.8	14.7	15.0	0.9
- 40-49.9	15.0	16.6	12.1	0.008
- 50-59.9	19.0	20.1	17.0	0.09
- 60-69.9	13.8	16.1	9.7	< 0.001
- 70-79.9	13.2	14.1	11.7	0.13
- ≥80	20.8	14.6	31.8	< 0.001
Male gender, %	45.7	50.2	37.9	< 0.001
Hypertension, %	31.2	32.9	28.4	0.038
Diabetes, %	12.3	10.6	15.2	0.003
Major cardiovascular diseases, %	16.6	14.6	20.1	0.002
COPD, %	5.6	6.0	5.0	0.4
Cancer, %	7.7	8.3	6.6	0.2
Renal diseases, %	5.9	5.0	7.4	0.029

^a From March 3 to March 31.

Overall, 177 persons deceased (after a mean of 11.7 days of follow-up): 135 of the 1244 subjects diagnosed in March, 42 of the 702 subjects diagnosed in April. The mean age of those who died substantially increased: it was 77.9±10.8 for those diagnosed in March, 86.9±7.7 for those detected in April (p<0.001). In March, 28 of those deceased were younger than 70 years, and 8 were younger than 60 years. In April, a single death occurred in subjects younger than 70 years.

From March to April, the overall case-fatality rate significantly decreased (10.8% versus 6.0%, respectively;

From March to April, the overall case-fatality rate significantly decreased (10.8% versus 6.0%, respectively p<0.001 - Fig 1).

^b From April 1 to April 25.

^{*} Chi-squared test for categorical variables, t-test for continuous ones.

Figure 1. SARS-CoV-2 case-fatality rate in the first two months of the pandemic (March and April, 2020), overall and stratified for the most frequent risk classes (all p<0.05). Vertical bars are referred to 95% confidence intervals.

As shown in Table 2, a reduction of SARS-CoV-2 lethality was observed in any age-class and any category of risk. The decrease was however larger among the subjects at higher risk of death: with the lethality dropping from 23.4% to 6.1% in the age-class 70-79y, and from 36.3% to 16.1% among the elderly (80+ years); both p<0.05. Similar reductions of the case-fatality rate were observed among the subjects with hypertension (from 23.0% to 12.1%), diabetes (from 30.3% to 8.4%), CVD (from 31.5% to 12.1%), COPD (from 29.7% to 11.4%), and renal disease (from 32.3% to 11.5%; all univariate p-values<0.05).

Table 2. Proportion of deaths, overall and by time of SARS-CoV-2 infection diagnosis after the first case (March 3, 2020), and hazard ratios (HRs) predicting the time to death of patients diagnosed in April vs March 2020.

	Total sample	March 2020 ^a	April 2020 ^b	P ^c	April vs March HR (95% CI)	$\mathbf{P}^{\mathbf{d}}$
Overall	9.1	10.8	6.0	< 0.001	0.42 (0.29-0.60)	< 0.001

Age-class in years, %						
-<18	0.0	0.0	0.0			
- 18-39.9	0.0	0.0	0.0			
- 40-49.9	0.7	1.0	0.0	0.4		
- 50-59.9	1.9	2.4	0.8	0.3	0.37 (0.04-3.32)	0.4
- 60-69.9	7.5	10.0	0.0	0.007		
- 70-79.9	17.9	23.4	6.1	0.001	0.31 (0.12-0.79)	0.014
- ≥80	25.2	36.3	16.1	< 0.001	0.51 (0.33-0.77)	0.002
Gender, %						
- Females	8.0	9.0	6.4	0.12	0.43 (0.27-0.69)	< 0.001
- Males	10.4	12.7	5.3	0.001	0.35 (0.19-0.62)	< 0.001
Hypertension, %						
- No	4.4	4.9	3.6	0.3	0.43 (0.24-0.78)	0.005
- Yes	19.4	23.0	12.1	0.001	0.45 (0.28-0.72)	0.001
Diabetes, %						
- No	7.5	8.5	5.6	0.025	0.44 (0.29-0.68)	< 0.001
- Yes	20.5	30.3	8.4	< 0.001	0.36 (0.17-0.76)	0.007
Major cardiovascular						
diseases, %						
- No	6.3	7.3	4.5	0.023	0.49 (0.30-0.79)	0.003
- Yes	23.0	31.5	12.1	< 0.001	0.37 (0.21-0.66)	0.001
COPD, %						
- No	8.2	9.7	5.7	0.003	0.49 (0.33-0.72)	< 0.001
- Yes	23.9	29.7	11.4	0.036	0.26 (0.08-0.82)	0.022

8.2	9.8	5.5	0.001	0.43 (0.29-0.64)	< 0.001
19.5	22.3	13.0	0.2	0.47 (0.19-1.18)	0.11
8.2	9.7	5.5	0.002	0.48 (0.32-0.72)	< 0.001
22.8	32.3	11.5	0.009	0.20 (0.07-0.54)	0.002
	8.2	19.5 22.3 8.2 9.7	19.5 22.3 13.0 8.2 9.7 5.5	19.5 22.3 13.0 0.2 8.2 9.7 5.5 0.002	19.5 22.3 13.0 0.2 0.47 (0.19-1.18) 8.2 9.7 5.5 0.002 0.48 (0.32-0.72)

^a From March 3 to March 31.

CVD, COPD, cancer and renal disease, the hazard ratio (HR) of death of those diagnosed in April, as compared to March, was 0.42 (95% Confidence Interval - CI: 0.29-0.60 - Table 2). With the only exception of the subjects with history of cancer, a significantly, considerably lower likelihood of death was observed in any subset of the sample, with HRs ranging from 0.20 among the subjects with renal disease, up to 0.51 among those aged 80 years or more (Table 2). The results of the random-effect logistic regression did not vary: overall, the adjusted odds ratio of death at 20 days was 0.29 (95% CI: 0.19-0.45; p<0.001) for those diagnosed in April, as compared to the subjects detected in March.

Discussion

This study provides the first evidence of a considerable decrease of SARS-CoV-2 case-fatality rate over time. From March to April 2020, the death rate decreased by more than 50% in all age-classes, being larger among the subjects with the highest risk of death because of comorbidities [13, 14]. This finding was confirmed in all multivariable analyses, adjusting for several potential confounders.

It is complex to discern which could be the potential reasons for the observed, entirely novel findings. The first, most obvious explanation, is that the healthcare system might have been overcrowded during the epidemic peak in March, with a loss of efficacy [15]. This is however very unlikely to apply to the present sample, because SARS-CoV-2 infection rates were relatively low - and never exceeded the capacity of the intensive care units - in the two provinces under analysis [16].

^b From April 1 to April 25.

^c Chi-squared test for categorical variables, t-test for continuous ones.

^d Cox proportional hazard model, adjusted for age, gender, hypertension, diabetes, major cardiovascular diseases, COPD, cancer and renal disease. Some models could not be fit due to the scarce number of deaths.

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

Other potential, non mutually exclusive explanations include virus mutation and substantial improvements in the organization (including the expansion of dedicated hospital beds), therapy and management of the infected subjects. Some scientists suggested that a less virulent viral strain, with consequent reduced lethality, might emerge during the pandemic [10]. Alternatively, the infection might have accelerated the clinical path of the most fragile individuals in the earlier phases. Both hypotheses, however, are currently unsubstantiated by data [17]. Concerning the therapy, a growing number of clinicians suggest that the current therapeutic approach, based upon the early administration of more tailored medications, is considerably improving the clinical course of COVID-19 [7-9, 11]. In the two provinces under investigation, the treatment is currently based upon antiviral agents (lopinavir / ritonavir), intensive respiratory support [18, 19], and, from the latest days of March, low molecular weight heparin and monoclonal antibodies against inflammatory cytokines (e.g. tocilizumab), which showed some preliminary, promising results [18, 20-23]. Given that available data are anecdotal, and no therapeutics is currently recommended for or against SARS-CoV-2 infection or disease [24], only the results of the several randomized trials that are being conduced on the above treatments [18, 25], will permit to discern which approach, and to what extent, contributed to the improvement of SARS-CoV-2 infection prognosis. The main limitations of the study are the inclusion of only two provinces from a single country, and the lack of data on body mass index, which is emerging as significant predictor of death from COVID-19 [26, 27]. In conclusion, the present study provided evidence of a significant, considerable decrease of SARS-CoV-2 case-fatality rate between March and April, 2020, supporting preliminary claims on a substantial improvement of the therapeutic approaches. The findings are inevitably preliminary and require confirmation from further datasets and ongoing randomized trials.

Acknowledgments

The authors are grateful to Dr. Giorgia Valpiani and Dr. Nicola Napoli for their valuable help in data collection.

Financial disclosure statement: This work was not funded.

Competing interests: All authors declare that they have no potential conflict of interest.

References

214

215

- 217 1. COVID-19 Coronavirus Outbreak [Internet]. Dadax. 2020 [cited March 14, 2020]. Available from:
- 218 https://www.worldometers.info/coronavirus/.
- 219 2. Johns Hopkins University & Medicine. Coronavirus Resource Center Mortality Analyses 2020
- [May 16, 2020]. Available from: https://coronavirus.jhu.edu/data/mortality.
- 221 3. Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, et al. Demographic science aids in
- 222 understanding the spread and fatality rates of COVID-19. Proc Natl Acad Sci U S A. 2020;117(18):9696-8.
- 223 Epub 2020/04/18. doi: 10.1073/pnas.2004911117
- 224 2004911117 [pii]. PubMed PMID: 32300018.
- 225 4. Boccia S, Ricciardi W, Ioannidis JPA. What Other Countries Can Learn From Italy During the
- 226 COVID-19 Pandemic. JAMA internal medicine. 2020. Epub 2020/04/08. doi:
- 227 10.1001/jamainternmed.2020.1447. PubMed PMID: 32259190.
- 5. Iosa M, Paolucci S, Morone G. Covid-19: A Dynamic Analysis of Fatality Risk in Italy. Front Med.
- 229 2020;7:185. doi: 10.3389/fmed.2020.00185.
- 230 6. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in
- 231 Relation to COVID-19 in Italy. JAMA. 2020. Epub 2020/03/24. doi: 10.1001/jama.2020.4683
- 232 2763667 [pii]. PubMed PMID: 32203977.
- 233 7. Furuya K, Kato K, Nagata I, Makimura N. [Studies on the blood constituents of the neonates
- delivered by the induced delivery of the Defense Medical College method]. Nihon Sanka Fujinka Gakkai
- 235 Zasshi. 1986;38(2):215-22. Epub 1986/02/01. PubMed PMID: 3457089.
- 236 8. Sano M, Sakagami M, Harada T, Matsunaga T, Tominaga Y, Nakayama M. Histopathology of the
- temporal bones in thanatophoric dysplasia. Med J Osaka Univ. 1991;40(1-4):51-7. Epub 1991/03/01.
- 238 PubMed PMID: 1369657.
- 239 9. Scientists disagree: the virus is losing its virulence, but it is forbidden to say it [Quella faida tra
- scienziati sul virus: è indebolito ma è vietato dirlo]. Il Giornale. May 11, 2020.

- 241 10. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the Origin and Continuing Evolution of
- SARS-CoV-2. National Science Review. 2020;nwaa036. doi: https://doi.org/10.1093/nsr/nwaa036.
- 243 11. Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, et al. Off-label Use
- 244 of Tocilizumab in Patients with SARS-CoV-2 Infection. Journal of medical virology. 2020. Epub
- 245 2020/04/17. doi: 10.1002/jmv.25897. PubMed PMID: 32297987.
- 246 12. Manzoli L, La Vecchia C, Flacco ME, Capasso L, Simonetti V, Boccia S, et al. Multicentric cohort
- 247 study on the long-term efficacy and safety of electronic cigarettes: study design and methodology. BMC
- 248 Public Health. 2013;13:883. Epub 2013/09/26. doi: 10.1186/1471-2458-13-883
- 249 1471-2458-13-883 [pii]. PubMed PMID: 24063569; PubMed Central PMCID: PMC3853622.
- 250 13. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors
- associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult
- 252 NHS patients [submitted]. MedRxiv. 2020. Epub May 7, 2020. doi:
- 253 https://doi.org/10.1101/2020.05.06.20092999.
- 254 14. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and
- 255 Mortality in Covid-19. N Engl J Med. 2020. Epub 2020/05/02. doi: 10.1056/NEJMoa2007621. PubMed
- 256 PMID: 32356626.
- 257 15. Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive care management of
- 258 coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med.
- 259 2020;8(5):506-17. Epub 2020/04/10. doi: S2213-2600(20)30161-2 [pii]
- 260 10.1016/S2213-2600(20)30161-2. PubMed PMID: 32272080; PubMed Central PMCID: PMC7198848.
- 261 16. ProtezioneCivile. COVID-19 Italia Monitoraggio della situazione 2020 [April 6, 2020]. Available
- 262 from:
- 263 http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1.
- 264 17. MacLean O, Orton RJ, Singer JB, Robertson D. No evidence for distinct types in the evolution of
- 265 SARS-CoV-2. Virus Evolution. 2020;6(1):veaa034. doi: 10.1093/ve/veaa034.
- 266 18. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus
- 267 Disease 2019 (COVID-19): A Review. JAMA. 2020. Epub 2020/04/14. doi: 10.1001/jama.2020.6019
- 268 2764727 [pii]. PubMed PMID: 32282022.

- 269 19. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases
- 270 Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clinical
- 271 infectious diseases : an official publication of the Infectious Diseases Society of America. 2020. Epub
- 272 2020/04/28. doi: 10.1093/cid/ciaa478. PubMed PMID: 32338708; PubMed Central PMCID: PMC7197612.
- 273 20. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose
- tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020. Epub
- 275 2020/05/15. doi: 10.1016/j.ejim.2020.05.009
- 276 S0953-6205(20)30194-1 [pii]. PubMed PMID: 32405160; PubMed Central PMCID: PMC7219361.
- 277 21. Mazzitelli M, Arrighi E, Serapide F, Pelle MC, Tassone B, Lionello R, et al. Use of subcutaneous
- 278 tocilizumab in patients with COVID-19 pneumonia. J Med Virol. 2020. Epub 2020/05/16. doi:
- 279 10.1002/jmv.26016. PubMed PMID: 32410234.
- 280 22. AIFA. LMWH in adult COVID-19 patients [Eparine a basso peso molecolare nei pazienti adulti con
- 281 COVID-19]. In: Italian, Medicines, Agency, editors. Rome2020.
- 282 23. American Society of H. COVID-19 and VTE/Anticoagulation. 2020 May 18, 2020. Report No.
- 283 24. CDC CfDCaP. Information for Clinicians on Investigational Therapeutics for Patients with COVID-
- 284 19: CDC; 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html.
- 285 25. World Health Organization. Data visualizations and mapping of registered studies for COVID-19
- 286 experimental treatments. 2020.
- 287 26. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of
- obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical
- 289 ventilation. Obesity (Silver Spring). 2020. Epub 2020/04/10. doi: 10.1002/oby.22831. PubMed PMID:
- 290 32271993.

- 291 27. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, François F, et al. Obesity in patients
- younger than 60 years is a risk factor for Covid-19 hospital admission. Clinical infectious diseases: an
- 293 official publication of the Infectious Diseases Society of America. 2020. Epub 2020/04/10. doi:
- 294 10.1093/cid/ciaa415. PubMed PMID: 32271368; PubMed Central PMCID: PMC7184372.

Figure 1.

298

